VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
10 nov. 2017 08h00 HE
|
VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
02 nov. 2017 08h00 HE
|
VBI Vaccines, Inc.
Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of DirectorsPontifax’s participation in the recent financing was alongside investments from several new fundamental...
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
31 oct. 2017 08h30 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
30 oct. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
26 oct. 2017 09h29 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
25 oct. 2017 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Additional Details Relating to the SciVac Therapeutics and VBI Vaccines Merger Transaction
09 mai 2016 15h02 HE
|
VBI Vaccines, Inc.
SciVac Therapeutics changed its name to VBI VaccinesOn May 6, 2016, each share of VBI Vaccines common stock was converted into the right to receive 0.520208 common shares of post-merger VBI VaccinesOn...
SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction
09 mai 2016 08h30 HE
|
VBI Vaccines, Inc.
SciVac Therapeutics changes its name to VBI VaccinesCombined company to begin trading on The NASDAQ Capital Market under the symbol “VBIV”Combined company is a biotechnology company with a licensed...
VBI Vaccines to Present at the Bloom Burton Healthcare Investor Conference
28 avr. 2016 08h30 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”) is scheduled to present at the Bloom Burton Healthcare Investor Conference on Monday, May 2nd at 1:30 PM...
VBI Vaccines and SciVac Therapeutics Announce Effectiveness of Registration Statement on Form F-4
14 avr. 2016 08h30 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”) and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) (“SciVac”) announced today that the registration...